Skip to content
Siegfried
-
Halo Pharma resurfaces as stand-alone CDMO following strategic Siegfried acquisitions
The divestment positions Halo to focus on expanding into more complex drug-product manufacturing services while strengthening its presence in the sterile CDMO market.